ArticleGynecologic oncology reports2019
Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing.
Article in Gynecologic oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Multi-omics profiling reveals homologous recombination repair hyperactivation as a therapeutic vulnerability in neuroendocrine cervical carcinoma.Signal transduction and targeted therapy · 2026Article
- Recent progress and therapeutic strategies in the treatment of cervical neuroendocrine neoplasms (Review).International journal of molecular medicine · 2026Review
- Durable complete remission of pulmonary metastases with bevacizumab plus olaparib maintenance therapy in homologous recombination-deficient gynecologic large-cell neuroendocrine carcinoma: A case report.Gynecologic oncology reports · 2026Article
- Clinical outcomes of neuroendocrine carcinoma of the cervix: Retrospective review from a large academic cancer centre.Gynecologic oncology reports · 2025Article
- Large-Cell Neuroendocrine Carcinoma of the Cervix: Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Case Report: Deep and durable response to talazoparib in germlineFrontiers in oncology · 2025Article
- Article
- Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).Journal of gynecologic oncology · 2022Review
- Article
- Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix.Frontiers in pharmacology · 2022Review
- Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities.Molecular oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
•This case reports the treatment of neuroendocrine carcinoma of the cervix with a PARPi based on NGS.•NGS reports have demonstrated somatic mutations BRCA in neuroendocrine carcinoma of the cervix.•The use of a PARPi in neuroendocrine carcinoma of the cervix has not been previously reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.